10X Genomics, Inc. (TXG)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$62.65-0.90%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · TXG
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 103.5% |
| Our one-year growth estimate | diamond | 7.4% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 96.1 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
TXG — General Counsel transition
Dated 2025-11-14
Chief Legal Officer — Eric S. Whitaker: Eric S. Whitaker is retiring as Chief Legal Officer and will transition to Strategic Counsel, with Dr. Randy Wu succeeding him.
Why it matters: Higher gross margins show better cost control. A drop may mean issues in operations.
Supportive ifGross margin exceeds 75% in Q3 2026.
Worry ifGross margin drops below 72% in Q3 2026.
Why it matters: If revenue growth picks up, it could signal a positive shift for 10X Genomics. The sector's health impacts the company directly.
Supportive ifSector revenue growth rises back toward 10% year over year.
Worry ifSector revenue growth is slowing down. It is now below 10% year over year.
Why it matters: Positive cash flow means better financial health. It also shows efficiency.
Supportive ifQ3 cash flow from operations is positive after earlier drops.
Worry ifQ3 cash flow from operations remains negative.
Why it matters: Confirming the raised revenue guidance shows management's confidence in growth. It impacts investor trust.
Supportive ifManagement confirms Q3 revenue guidance remains within the raised range of $610M to $630M.
Worry ifManagement revises Q3 revenue guidance down from the current range.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$282 on $10,000 · ±2.8% | How much price usually moves either way. |
| Bad day | $585 loss on $10,000 · 5.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,803 loss on $10,000 · 28.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Revenue from Atera shows that the new platform is doing well in the market.
Supportive ifAtera generates at least $10 million in revenue by the end of Q4 2026.
Worry ifAtera fails to generate any revenue by the end of Q4 2026.
Why it matters: Positive cash flow is important for financial health. It helps keep operations stable.
Supportive ifCash from operations is over $26M in Q2. This shows strong performance.
Worry ifCash from operations falls below $26M. This may mean there are operational issues.
Why it matters: Improving cash flow from operations shows better financial health. Continued declines could raise concerns.
Supportive ifCash from operations increases above $20 million in Q3 2026.
Worry ifCash from operations drops below $16 million in Q3 2026.
Why it matters: Sales updates on Atera will show if the product launch meets expectations. Strong sales can boost overall revenue.
Supportive ifManagement shares early sales numbers. They also report strong orders for the Atera platform.
Worry ifSales numbers for Atera are lower than expected or show weak demand.
Why it matters: Growth in consumables is vital for sustaining revenue and market share.
Supportive ifSingle cell consumables revenue grows by double digits in Q2.
Worry ifSingle cell consumables revenue growth slows to single digits or drops.
Why it matters: The earnings report will provide insights on revenue, cash flow, and margins. It is a key event for investors.
Watch forEarnings report shows positive results across key metrics.
Also watch forEarnings report shows negative results across key metrics.
Why it matters: Successful shipments of Atera could lead to more revenue. This may increase market interest.
Supportive ifAtera platform begins shipping to customers in Q3 2026.
Worry ifShipments of Atera are delayed beyond Q3 2026.